Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Neuromyelitis Optica (Devics Syndrome)-Pipeline Review, H1 2015

Neuromyelitis Optica (Devics Syndrome)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Neuromyelitis Optica (Devic's Syndrome)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Neuromyelitis Optica (Devic's Syndrome)-Pipeline Review, H1 2015', provides an overview of the Neuromyelitis Optica (Devic's Syndrome)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neuromyelitis Optica (Devic's Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic's Syndrome)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Neuromyelitis Optica (Devic's Syndrome) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Neuromyelitis Optica (Devic's Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Neuromyelitis Optica (Devic's Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Neuromyelitis Optica (Devic's Syndrome)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic's Syndrome) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Neuromyelitis Optica (Devic's Syndrome) Overview 7

Therapeutics Development 8

Pipeline Products for Neuromyelitis Optica (Devic's Syndrome)-Overview 8

Pipeline Products for Neuromyelitis Optica (Devic's Syndrome)-Comparative Analysis 9

Neuromyelitis Optica (Devic's Syndrome)-Therapeutics under Development by Companies 10

Neuromyelitis Optica (Devic's Syndrome)-Therapeutics under Investigation by Universities/Institutes 11

Neuromyelitis Optica (Devic's Syndrome)-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Neuromyelitis Optica (Devic's Syndrome)-Products under Development by Companies 15

Neuromyelitis Optica (Devic's Syndrome)-Products under Investigation by Universities/Institutes 16

Neuromyelitis Optica (Devic's Syndrome)-Companies Involved in Therapeutics Development 17

Acorda Therapeutics, Inc. 17

Alexion Pharmaceuticals, Inc. 18

Chugai Pharmaceutical Co., Ltd. 19

HanAll Biopharma Co., Ltd. 20

MedImmune, LLC 21

Opexa Therapeutics, Inc. 22

Shenzhen Beike Biotechnology Co., Ltd. 23

Shire Plc 24

Takeda Pharmaceutical Company Limited 25

Neuromyelitis Optica (Devic's Syndrome)-Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Combination Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

C1 esterase inhibitor (human)-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

dalfampridine ER-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Dendritic Cell Therapy for Central Nervous System Disorders-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

eculizumab-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

HL-161-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

immune globulin (human)-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

MEDI-551-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

NU-21101 + NU-21502-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

OPX-212-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

SA-237-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Neuromyelitis Optica (Devic's Syndrome)-Recent Pipeline Updates 52

Neuromyelitis Optica (Devic's Syndrome)-Product Development Milestones 64

Featured News & Press Releases 64

Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica 64

Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program 65

Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis 65

Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall-Visible Particles 67

Dec 13, 2013: Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris Concentrated Solution for Intravenous Infusion 67

Jul 16, 2013: Alexion's Soliris Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica 68

Jun 27, 2013: Alexion Pharma's Soliris Receives FDA Orphan Drug Designation For Treatment Of Neuromyelitis Optica 68

Oct 09, 2012: Alexion Pharma Announces Presentation Of Phase II Study Data Of Eculizumab In Patients With Relapsing Neuromyelitis Optica At ANA Annual Meeting 69

Appendix 71

Methodology 71

Coverage 71

Secondary Research 71

Primary Research 71

Expert Panel Validation 71

Contact Us 71

Disclaimer 72

List of Tables

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H1 2015 8

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Products under Investigation by Universities/Institutes, H1 2015 16

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Acorda Therapeutics, Inc., H1 2015 17

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 18

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 19

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 20

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by MedImmune, LLC, H1 2015 21

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Opexa Therapeutics, Inc., H1 2015 22

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Shenzhen Beike Biotechnology Co., Ltd., H1 2015 23

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Shire Plc, H1 2015 24

Neuromyelitis Optica (Devic's Syndrome)-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 25

Assessment by Monotherapy Products, H1 2015 26

Assessment by Combination Products, H1 2015 27

Number of Products by Stage and Target, H1 2015 29

Number of Products by Stage and Mechanism of Action, H1 2015 31

Number of Products by Stage and Route of Administration, H1 2015 33

Number of Products by Stage and Molecule Type, H1 2015 35

Neuromyelitis Optica (Devic's Syndrome) Therapeutics-Recent Pipeline Updates, H1 2015 52

List of Figures

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H1 2015 8

Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 13

Assessment by Monotherapy Products, H1 2015 26

Number of Products by Top 10 Targets, H1 2015 28

Number of Products by Stage and Top 10 Targets, H1 2015 28

Number of Products by Top 10 Mechanism of Actions, H1 2015 30

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 30

Number of Products by Top 10 Routes of Administration, H1 2015 32

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32

Number of Products by Top 10 Molecule Types, H1 2015 34

Number of Products by Stage and Top 10 Molecule Types, H1 2015 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acorda Therapeutics, Inc.

Alexion Pharmaceuticals, Inc.

Chugai Pharmaceutical Co., Ltd.

HanAll Biopharma Co., Ltd.

MedImmune, LLC

Opexa Therapeutics, Inc.

Shenzhen Beike Biotechnology Co., Ltd.

Shire Plc

Takeda Pharmaceutical Company Limited

Neuromyelitis Optica (Devics Syndrome) Therapeutic Products under Development, Key Players in Neuromyelitis Optica (Devics Syndrome) Therapeutics, Neuromyelitis Optica (Devics Syndrome) Pipeline Overview, Neuromyelitis Optica (Devics Syndrome) Pipeline, Neuromyelitis Optica (Devics Syndrome) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com